Age-Related Macular Degeneration Market Report by Disease Type, Product, Distribution Channel, Country And Company Analysis 2026-2034

Age-Related Macular Degeneration (AMD) Market Size & Forecast 2026-2034

The Age-Related Macular Degeneration (AMD) market will see consistent growth during the forecast period, owing to the growing geriatric population and high incidence rate of visual disorders. The market will see a rise from US$ 12.21 Billion in 2025 to US$ 23.25 Billion in 2034, with a CAGR of 7.42% between 2026-2034, thanks to improvements in therapy, increased use of technology, and enhanced knowledge about early treatments among the global population.

Age-Related Macular Degeneration (AMD) Market Outlooks

Age-related macular degeneration (AMD) is an ocular disease associated with macula deterioration. The macula is a component of the retina located at the center, responsible for straight-ahead vision. Age-related macular degeneration typically develops in elderly individuals and results in gradual loss of central vision, which affects daily functions such as reading, driving, and face recognition. Age-related macular degeneration can be categorized into dry AMD and wet AMD, where the latter is more destructive since new blood vessels may develop within the eyes. This disease cannot be cured completely; however, treatment includes antivascular endothelial growth factor injection, lifestyle modification, and nutritional supplementation.

Age-related macular degeneration is extensively researched and treated by ophthalmologists since it is a prevalent disease across the globe, especially among aged people living in North America, Europe, and some areas in Asia. Furthermore, the popularity of this disease in biomedical research is on the rise because of increased life expectancy rates and heightened public consciousness regarding vision care. Early detection of age-related macular degeneration can be achieved through ocular screening, thus enhancing preventive measures against irreversible vision impairment.

Top 10 Geriatric Population Countries in 2025

Rank Country / Territory 65+ Share of Population (%)

1 Monaco 36.2%

2 Japan 29.8%

3 Puerto Rico 24.7%

4 Italy 24.6%

5 Portugal 24.5%

6 Greece 23.9%

7 Finland 23.9%

8 Germany 23.2%

9 Croatia 23.2%

10 Serbia 22.7%

Sources: StatRanker and Renub Research

Top 10 ophthalmology Prevalence worldwide

Rank Ophthalmology Disorder Estimated Global Prevalence in 2025

1 Refractive Errors 2.2 Billion+ Cases

2 Presbyopia 1.8 Billion+ Cases

3 Dry Eye Disease 344 Million+ Cases

4 Cataract 94 Million+ Cases

5 Diabetic Retinopathy 146 Million+ Cases

6 Glaucoma 76 Million+ Cases

7 Age-Related Macular Degeneration (AMD) 196 Million+ Cases

8 Corneal Blindness / Corneal Opacity 12.7 Million+ Cases

9 Trachoma 1.9 Million Blindness Cases

10 Retinitis Pigmentosa 1.5 Million+ Cases

Source: World Health Organization, global vision studies and Renub Research

Growth Drivers of the Age-Related Macular Degeneration Market

Rising Geriatric Population and Disease Prevalence

Age-Related Macular Degeneration is greatly related to the process of aging; hence, an increase in the number of aged people is expected to propel the market significantly. The rise in life expectancy levels across different continents has resulted in a high rate of people aging beyond 60 or even 70 years in places such as North America, Europe, and selected countries within Asia Pacific. Consequently, there will be more patients suffering from Age-Related Macular Degeneration owing to the aforementioned increase in the population of aged people. Considering that this disorder is among the main causes of blindness in older patients, there will be high demand for diagnostic, monitoring, and treatment services in relation to AMD. Additionally, the health care sector has been promoting screening campaigns, a move aimed at diagnosing more cases of AMD. By the year 2030, one in six people in the world will have attained the age of 60 years and above. In the year 2030, the number of people aged 60 years and older will rise from one billion in 2020 to 1.4 billion. The total number of people aged 60 years and above will be double that of 2020 by the year 2050 (2.1 billion).

Advancements in Treatment Options and Drug Innovation

Innovation in ophthalmology is continuously playing a vital role in stimulating the market for AMD. The introduction of anti-VEGF agents has dramatically altered the management of wet AMD, assisting in delaying or even stabilizing vision impairment. Several pharmaceutical companies are developing new generations of drugs that will be injected less often. This is important since it enhances adherence and patient compliance. Gene therapies and prolonged-release formulations are other innovations expected to transform the market. The expansion of research on the condition by conducting numerous clinical studies has also contributed to the emergence of various drug pipelines against AMD. Advancements in formulation technology and personalized treatment have significantly boosted therapeutic efficiency. The existence of better and more manageable treatments contributes to increasing the uptake of drugs. Therefore, innovation in the pharmaceutical sector is an important catalyst for market development. Astellas Pharma revealed in February 2025 that FDA had approved labeling expansion for IZERVAY(TM) (avacincaptad pegol intravitreal solution) for the treatment of GA caused by AMD. This means that FDA has now approved the administration of IZERVAY(TM) without any restrictions regarding the length of the drug regimen used in the treatment of GA.

Growing Awareness and Improved Diagnostic Capabilities

Rising awareness levels with respect to eye health are also one of the key factors that have been fueling the global AMD market. Public awareness campaigns, along with eye examination programs, have enabled a rise in early diagnosis rates. Modern diagnostic methods, such as OCT and fundus imaging, have enabled physicians to detect signs of AMD in their patients at an earlier stage than before. This allows them to provide proper treatment, thus delaying the progress of the condition and maintaining the patient's vision capabilities. In addition, the patient awareness level regarding the need to visit an eye doctor on a regular basis has risen due to various campaigns conducted through digital media and healthcare awareness campaigns. The use of advanced technology and equipment for diagnostic procedures by hospitals and eye clinics has also helped boost the market further. Eye examination insurance coverage in certain regions has enabled the population to access diagnostic procedures easily. Prevent Blindness, the country's largest non-profit eye health and safety organization, is designating the month of February as AMD and Low Vision Awareness Month. Prevent Blindness will be providing various free educational materials for the public and professionals alike, such as information sheets and social media graphics in English and Spanish, as well as specialized web pages and videos.

Challenges of the Age-Related Macular Degeneration Market

High Treatment Costs and Economic Burden

Another problem faced in the Age-Related Macular Degeneration market is the high price of long-term treatment. Treatment of Age-Related Macular Degeneration (particularly wet AMD), requires frequent intra-vitreal administration of anti-VEGF medicines that are costly for both the patient and the healthcare system. In many parts of the world, especially developing countries, the price of therapy becomes a problem, causing barriers in treatment compliance. High cost is an obstacle even for developed markets where self-paying people and patients covered by some limited insurance programs do not have access to best-in-class therapy. The high cost of diagnosis and follow-up procedures also adds up to treatment expenditure. Such expenses could result in late therapy or discontinuing treatment, leading to poor results. Although there are numerous available treatment options, cost is still a limitation factor preventing broader use, thus restraining the growth of the market.

Limited Curative Treatments and Disease Complexity

A third problem associated with treating AMD concerns the fact that there is no cure for this condition. Most treatment methods currently applied concentrate on alleviating the symptoms of the disease by retarding its progress. In this regard, people suffering from AMD have to rely on continuous use of medication and regular checks conducted by ophthalmologists to prevent the development of further complications and maintain current levels of vision as much as possible. The multifactorial nature of the disease renders the task of finding a universally applicable solution difficult for researchers. Although anti-VEGF drugs have proven highly effective for many individuals diagnosed with AMD, they do not work in all cases and need frequent administration. Additionally, dry AMD affects considerably more patients than wet AMD but offers fewer treatment possibilities. At the moment, gene therapy and regenerative medicine hold great promise and can be considered as potential cure, but much work remains to be done.

Dry Age-Related Macular Degeneration Market

DRY Age-Related Macular Degeneration constitutes the largest share of the Age-Related Macular Degeneration Market, making up close to 80-90% of all diagnosed cases around the globe. This type of disease develops at a relatively slower pace compared to other types, owing to the gradual degeneration of the macula coupled with drusen accumulation in the macula. The growth drivers include the unavailability of a curative therapy; thus, there is a constant need for treatment options such as complementary treatments, supplements, and complement inhibitors in development. Rising prevalence of aging populations coupled with better diagnostic screening is expected to increase the identification rate of patients around the world. Moreover, studies centered on treating geographic atrophy hold commercial appeal, whereas rising awareness about eye health in its initial stage is creating a need for preventative treatment options. The inability to treat ARMD results in limited treatment options, thus creating opportunities for continuous monitoring.

Eylea Age-Related Macular Degeneration Market

Eylea (aflibercept) is an important drug within the context of the treatment of wet Age-related Macular Degeneration. Eylea (aflibercept) is an anti-VEGF medication that helps in the prevention of excessive retinal blood vessels growth and leakage. This drug has been gaining ground in recent years because of its higher efficiency and ability to be administered at a relatively longer interval than previous drugs. The drug is mostly used in hospitals and specialized eye clinics which ensure strong demand worldwide. Factors that contribute to the market's growth include rising cases of wet AMD, aging population, and effective results obtained by using the drug. Doctors favor Eylea because of its safe use and ability to preserve visual acuity. The main drawbacks include a need for frequent intraocular injections as well as high cost of the treatment. Nonetheless, despite competition in this area, Eylea still enjoys popularity.

Lucentis Age-Related Macular Degeneration Market

Lucentis (ranibizumab) has been among the first innovative therapies for treating wet Age-Related Macular Degeneration. This medicine acts by inhibiting abnormal blood vessels growth within the retina and preventing vision loss. In addition, it plays an important role in setting standards of current treatments for macular degeneration and is widely used in various healthcare systems across the world. The drug is characterized by high demand as a result of strong clinical validation, physicians' recognition, and use within various treatment guidelines for retinal disorders. Administration of the medicine requires routine injections, therefore, a consistent follow-up from patients. However, there is some competition coming from other drugs, which require less frequent doses. Nevertheless, this therapy still maintains its relevance in areas with well-established reimbursement systems and hospital environment. Competition in the market is also associated with biosimilars that impact drug prices. However, Lucentis still enjoys good adoption rates owing to its strong recognition.

Beovu Age-Related Macular Degeneration Market

Beovu (brolucizumab), belonging to a new generation of anti-VEGF medication, is prescribed to patients suffering from wet Age-related Macular Degeneration. The main advantage of Beovu is the provision of prolonged dosing periods, thereby decreasing the need for intravitreal injection procedures compared to previous medications. In addition, the use of the drug is associated with better compliance with the treatment regime since patients are required to visit the physician less often. Beovu has been introduced into the market mainly due to its high efficiency in fluid removal from the retina, which contributes to the stabilization of visual functions. Market development is fueled by the rising interest in new therapies providing the benefits of a reduced number of procedures and favorable treatment outcomes. Safety risks related to inflammation in individual cases have hindered the broad introduction of Beovu in some regions. Nevertheless, current scientific evidence helps to reinforce its position in the sphere of AMD treatment.

Age-Related Macular Degeneration Hospital Pharmacy Market

Hospital pharmacies form an important market segment when it comes to the provision of treatments for Age-Related Macular Degeneration. Modern methods of treatment like anti-VEGF injections are mainly performed in hospitals and clinics, and therefore hospital pharmacies play a central role in providing supplies of these injections. They make sure that these expensive injections are delivered on time and stored properly before being used by physicians. Factors like increased eye care infrastructure in hospitals, higher numbers of patients, and the expansion of insurance cover in this field contribute to growth in the hospital pharmacy market for Age-Related Macular Degeneration treatment. Hospital facilities offer a convenient platform for diagnosing, monitoring, and administering follow-up treatments, which further adds to the importance of hospital pharmacies. However, there is a challenge in terms of the costs associated with this segment of the market together with the expertise of eye care specialists in performing the procedures.

United States Age-Related Macular Degeneration Market

United States emerges as a major market for Age-Related Macular Degeneration owing to its superior healthcare system, awareness about eye problems, and aging population. The nation is home to many patients suffering from dry as well as wet forms of AMD, which continuously fuels the demand for new-age therapies such as anti-VEGF therapy, retina imaging equipment, and ophthalmology. The strong emphasis on the conduct of clinical trials and pharmaceutical studies in the region promotes the emergence of breakthrough treatments like prolonged medications and genetics. Reimbursement policies and availability of eye specialists are additional factors promoting market expansion. Moreover, growing use of screening programs has led to the prompt diagnosis and treatment of AMD, contributing to better results. Availability of top-notch biotech and pharma companies has contributed to the competitive dynamics of the market. However, the high cost of treatment and lack of access to healthcare in rural America pose persistent challenges to AMD treatment.

United Kingdom Age-Related Macular Degeneration Market

The United Kingdom AMD market is witnessing consistent growth, attributed to increased awareness about eye conditions linked to age and greater need for targeted medical attention from eye care specialists. The expanding patient pool and easy access to healthcare services through public health services have helped drive market growth. In addition, the presence of effective screening and referral programs has helped ensure proper diagnosis and treatment of patients suffering from AMD. Hospital facilities and retinal clinics serve as important avenues for disease management, and the use of cutting-edge technology for diagnostic purposes is becoming increasingly common. Efforts by government agencies to facilitate the introduction of effective healthcare programs and clinical guidelines have helped promote standard treatments for the disease. Pharmaceutical firms have been making efforts to launch novel drugs that minimize injection frequency, thereby boosting patient adherence. However, issues such as long waitlists at hospitals and the rising burden on the nation's healthcare infrastructure could impede treatment access.

India Age-Related Macular Degeneration Market

India can be considered a fast-growing market for Age-Related Macular Degeneration because of the growing number of senior citizens in the country as well as an increase in the prevalence of vision problems. Awareness of the importance of eye health and the advancements made in healthcare infrastructure contribute to the rise in diagnosis cases in both urban and semi-urban parts of the nation. Specialty hospitals specializing in ophthalmology and retinal problems have been created, giving more people access to different AMD treatments, including anti-VEGF drugs and imaging equipment used for analyzing the retina. Additionally, government programs aimed at preventing blindness and creating eye health awareness help in the development of the market. Increased healthcare expenditure and the growth of the private sector in healthcare drive the adoption of new treatments for eyesight issues in India. Nonetheless, cost remains the main barrier to access as many people struggle to pay for prolonged treatments. In addition, a lack of awareness in rural areas and a shortage of retinal specialists hinder the widespread use of AMD medications.

Saudi Arabia Age-Related Macular Degeneration Market

Age-Related Macular Degeneration Market is experiencing slow growth in the kingdom owing to improved healthcare facilities, rising life expectancy rates, and awareness about chronic eye diseases. Healthcare infrastructure in the country is continuously advancing and developing, especially within ophthalmological services, making it easier for patients to access advanced diagnostic and treatment solutions for their health issues. Increased life expectancy rates coupled with the spread of lifestyle diseases like diabetes are also driving demand for retina diseases treatment. Anti-VEGF therapies and retinal imaging equipment have been increasingly being used by medical professionals within the country's hospitals and specialized clinics to improve patient results. Other factors contributing to growth in the ophthalmology market within the country include government healthcare reforms aimed at transforming healthcare in the region and an increase in the contribution of private healthcare facilities to the healthcare sector in the country.

Age-Related Macular Degeneration (AMD) Market Segments

Disease Type

• Dry Age-Related Macular Degeneration
• Wet Age-Related Macular Degeneration

Product

• Eylea
• Lucentis
• Beovu
• Others

Distribution Channel

• Hospital Pharmacy
• Specialty Pharma
• Online Pharmacy

Country

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE

All the Key players have been covered from 5 Viewpoints:

• Overview
• Key Persons
• Recent Development & Strategies
• Product Portfolio
• Financial Insights

Company Analysis:

• Hoffmann - La Roche Ltd.
• Bayer AG
• Abbvie
• GSK Plc
• Novartis AG
• Regeneron Pharmaceuticals
• Bausch Health Companies Inc.
• Alimera Sciences Inc.